BridgeBio Oncology Therapeutics, Inc. BBOT
BBOT is a clinical-stage biotechnology company with the mission of transforming the lives of patients with cancers driven by RAS and PI3Kα, the two most frequently mutated oncogenes. Aberrant RAS signaling drives uncontrolled tumor growth in some of the deadliest cancers, including lung, breast, pancreas and colon cancer. This can come from mutations in RAS itself, which underlie approximately 30% of all human cancers, or from RAS-mediated overactivation of PI3Kα. Our goal is to provide meaningful benefit to patients by designing and developing new therapies to achieve high levels of target inhibition against these oncogenic drivers while maintaining a favorable tolerability profile.
Our pipeline consists of three orally bioavailable small molecule inhibitors that were designed and optimized within BBOT with the goal to provide patients with significant benefit over standard of care. Additionally, we believe BBOT has the opportunity to provide further benefit to patients with KRAS mutant tumors through combination of our inhibitors. We believe our pipeline has the opportunity to address a large number of patients afflicted with metastatic cancer.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D | $121.2M | $73.1M | — | — |
| SG&A | $24.6M | $7.8M | $41.7K | — |
| Total operating expenses | $145.8M | $80.9M | — | — |
| Operating income | -$145.8M | -$80.9M | -$41.7K | — |
| Pre-tax income | -$134.0M | -$74.3M | — | — |
| Income tax | $0 | $0 | — | — |
| Net income | -$134.0M | -$74.3M | -$41.7K | — |
| EPS, basic | -4.30 | -5,756.41 | — | — |
| EPS, diluted | -4.30 | -5,756.41 | — | — |
| Shares, diluted (wtd. avg.) | 31.1M | 12,903 | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $373.7M | $30.9M | $250.0K | — |
| Short-term investments | $51.8M | $124.8M | — | — |
| Total current assets | $432.4M | $158.7M | — | — |
| Property, plant and equipment | $956.0K | $490.0K | — | — |
| Total assets | $448.4M | $164.3M | $332.9K | — |
| Accounts payable | $1.4M | $3.1M | — | — |
| Total current liabilities | $35.0M | $19.6M | $396.5K | — |
| Total liabilities | $37.3M | $19.6M | $396.5K | — |
| Retained earnings | -$356.6M | -$222.5M | -$88.6K | — |
| Total equity | $411.1M | -$178.6M | -$115.6M | -$21.9K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$113.9M | -$55.0M | — | — |
| Depreciation and amortisation | $280.0K | $208.0K | — | — |
| Stock-based compensation | $5.9M | $4.4M | — | — |
| Capital expenditure | $606.0K | $49.0K | — | — |
| Investing cash flow | $73.3M | -$120.5M | — | — |
| Financing cash flow | $383.4M | $206.3M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-197901.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Net income | — | -$41.7K | -$74.3M | -$134.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |